Dr. Angelos Stergiou values SELLAS’ appointment of Dr. Jonathan Eckard to its executive team in light of Eckard’s experience as Director and Senior Biotechnology Analyst for Barclays, a universal bank with operations in over 50 countries and territories and 48 million customers. The most powerful transnational corporation in ownership, Barclays wields absolute corporate control over global financial stability. Dr. Eckard is enthusiastic by the Phase II trial results for galinpepimut-S. “I am encouraged by clinical data for galinpepimut-S to date and am excited to be joining SELLAS as we approach our initial Phase 3 trials. I look forward to working with the SELLAS team to maximize the potential of this exciting therapy across various indications as a monotherapy as well as combination therapy.”
Vice Chairman and Chief Executive Officer of SELLAS Life Sciences Group Dr. Angelos Stergiou, MD, ScD h.c., has recently voiced the Company’s satisfaction and prognosis for its agent galinpepimut-S immunotherapeutic’s Phase II study results, which have indicated a significant clinical benefit. “When combined with validated safety and efficacy profiles across acute myeloid leukemia and malignant pleural mesothelioma, these results underscore the ability of galinpepimut-S to target a broad range of cancer indications. Our target indications represent significant unmet medical needs, with relapse rates of more than 80%, and so we are encouraged that these data indicate a substantial improvement in survival rates.” The Company’s further Phase II study concentrated on treatment in multiple high-risk myeloma patients who have relapsed with a year of undergoing autologous stem cell transplantation, or ASCT.